Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties. Certain drugs remain controversial in the literature. This study aims to evaluate the effect of common concomitant medications and overall survival in metastatic breast cancer patients.
Data was collected from 1,500 metastatic breast cancer patients from eight phase III clinical trials from Project Data Sphere. Project Data Sphere is a non-profit organisation providing access to large datasets from control arms of cancer trials, to be used for novel outcome analyses. Concomitant medications assessed included aspirin, metformin, statins, cox-2 inhibitors, low molecular weight heparin, protein pump inhibitors and erythropoietin. Overall survival was estimated using the Kaplan-Meier method. The prognostic effects of concomitant medications and overall survival was assessed by the Cox proportional hazards models.
At the time of abstract submission, results have not been fully collected and interpreted. Data collection and interpretation will be completed by the time of the conference. Preliminary results indicate that cox-2 inhibitors and metformin may be associated with improved survival; and aspirin and LMWH may be associated with worsened survival.
Conclusion will be completed by the time of the conference. Preliminary conclusion: This data is hypothesis generating. Expansion of trials and quality of data will facilitate future analysis. The use of certain concomitant medications also reflects the patient’s co-morbidities and overall health status.
Common medications, metastatic breast cancer, project data sphere